JTJames Douglas Triplett

James Douglas Triplett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Douglas Triplett has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Association of Body Weight, Composition, and Anthropometric Indices of Obesity with the Presence of Diabetic Neuropathy in People with Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Observational Studies

    by Elham Hosseini‐Marnani, Amin Salehi‐Abargouei, Kimia Rostampour, Md Kamruzzaman, Shamim Shams Rad, James Triplett, Jessica A. Marathe, Karen L. Jones, Michael Horowitz, Chinmay S. Marathe

    Background and Aims: Obesity has been identified as an independent risk factor for the development of diabetic neuropathy in type 2 diabetes (T2D). However, the relationship of individual parameters relating obesity with diabetic neuropathy is poorly understood. We evaluated these relationships in this systematic review and meta‐analysis. Methods: PubMed, Scopus, Web of Science, and Embase were searched from 1980 to July 5, 2025, for observational studies comparing anthropometric measures, including body weight, visceral fat (%), body mass index (BMI), waist circumference (WC), and waist‐to‐hip ratio (WHR), between individuals with and without diabetic neuropathy. Mean differences (MDs), odds ratios (ORs), and hazard ratios (HRs) were pooled using random‐effects models. Subgroup and meta‐regression analyses explored sources of heterogeneity by neuropathy type, geographic region, study design, diabetes duration, and HbA1c. Results: Higher BMI was significantly associated with diabetic neuropathy (OR = 1.09; 95% CI: 1.02 to 1.16; MD = 0.55; 95% CI: 0.22 to 0.89). Central obesity was associated with neuropathy risk (WC MD = 2.05 cm; 95% CI: 1.15 to 2.94; HR = 1.25; 95% CI: 1.04 to 1.51; WHR MD = 0.01; 95% CI: 0.00 to 0.01). Associations were more evident for peripheral neuropathy than for autonomic neuropathy. Diabetes duration and HbA1c may contribute to the heterogeneity between studies. Conclusion: BMI and WC were consistently, albeit modestly, associated with diabetic neuropathy in individuals with T2D, whereas the difference in WHR was small and inconsistent across neuropathy subtypes. No significant differences were observed in either body weight or visceral fat between individuals with and without diabetic neuropathy.

  • A new first line choice? Has clopidogrel superseded aspirin for secondary prevention following selected minor ischaemic strokes?

    by Noreen Haidar Khan, Stephen Bacchi, James Douglas Triplett, Rudy Goh

  • GLP-1RA–Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies

    by James D. Triplett, Marcus V. Pinto, Nathan P. Young, Nathan P. Staff, Marathe S. Chinmay, Michael Horowitz, Catarina Aragon Pinto, Ruple S. Laughlin, Kamal Shouman, Sarah E. Berini, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat obesity and diabetes. Semaglutide, a GLP-1RA, is linked to nonarteritic ischemic optic neuropathy (NAION), macular edema, and retinopathy. Because diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) are associated with weight loss, we examined whether GLP-1RA usage is linked to these neuropathies. We conducted a retrospective case-controlled study from April 28, 2005 (the first GLP-1RA Food and Drug Administration approval), to December 25, 2024. Patients diagnosed with DLRPN or CFN were analyzed for GLP-1RA exposure and clinical characteristics. A control group, matched for age, sex, body mass index (BMI), and diabetes status, was used to assess for an association with GLP-1RA use. We identified 26 individuals who developed 27 DLRPN episodes, with median symptom onset 6 months (range 3-35 months) after GLP-1RA initiation. At onset, they had a median glycated hemoglobin A1c (HbA1c) reduction of 2.4% (range 1%-8.5%) and a BMI decrease of 4 units (range 1-15), reflecting a 13.9% (range 3.6%-28.5%) weight loss. Microvasculitis was present in 4 of 5 nerve biopsies. Among 77 individuals with CFN, 82 episodes developed, with a mean GLP-1RA duration of 15 months (range 1-112 months). In individuals with CFN, the median HbA1c reduction was 1.2% (range -0.4% to 5%) and the BMI decrease was 4 units (range 0-15), corresponding to a 15.7% (range 3.0%-37.0%) weight loss. Patients with DLRPN experienced greater HbA1c reductions than patients with CFN (2.4% vs 1.2%, p < 0.001). New NAION, macular edema, or retinopathy were not seen with episodes. Compared with controls, GLP-1RA users were 51% more likely to develop DLRPN (odds ratio [OR] 1.5, 95% CI 1.2-1.9, p = 0.0008) and 30% more likely to develop CFN (OR 1.3, 95% CI 1.0-1.5, p = 0.018). All episodes occurred after 2015, with 3 DLRPN events and 7 CFN events occurring between 2015 and 2019, rising to 24 and 70 cases in 2020-2024, reflecting increases of 700% and 900%. GLP-1RA use is associated with an increased likelihood of DLRPN and CFN. DLRPN and its associated nerve microvasculitis seem more strongly linked to metabolic changes, particularly significant HbA1c reductions, while CFN has compressive neuropathy characteristics and is more influenced by weight loss.


  • Short-Acting Neuromuscular Blockade Improves Inter-rater Reliability of Median Somatosensory Evoked Potentials in Post-cardiac arrest Prognostication

    by Tatsuya Oishi, James D. Triplett, Ruple S. Laughlin, Sara E. Hocker, Sarah E. Berini, Ernest M. Hoffman

    Background Although median nerve somatosensory evoked potentials are routinely used for prognostication in comatose cardiac arrest survivors, myogenic artifact can reduce inter-rater reliability, leading to unreliable or inaccurate results. To minimize this risk, we determined the benefit of neuromuscular blockade agents in improving the inter-rater reliability and signal-to-noise ratio of SSEPs in the context of prognostication. Methods Thirty comatose survivors of cardiac arrest were enrolled in the study, following the request from an intensivist to complete an SSEP for prognostication. Right and left median nerve SSEPs were obtained from each patient, before and after administration of an NMB agent. Clinical histories and outcomes were retrospectively reviewed. The SSEP recordings before and after NMB were randomized and reviewed by five blinded raters, who assessed the latency and amplitude of cortical and noncortical potentials (vs. absence of response) as well as the diagnostic quality of cortical recordings. The inter-rater reliability of SSEP interpretation before and after NMB was compared via Fleiss’ κ score. Results Following NMB administration, Fleiss’ κ score for cortical SSEP interpretation significantly improved from 0.37 to 0.60, corresponding to greater agreement among raters. The raters were also less likely to report the cortical recordings as nondiagnostic following NMB (40.7% nondiagnostic SSEPs pre-NMB; 17% post-NMB). The SNR significantly improved following NMB, especially when the pre-NMB SNR was low (< 10 dB). Across the raters, there were three patients whose SSEP interpretation changed from bilaterally absent to bilaterally present after NMB was administered (potential false positives without NMB). Conclusions NMB significantly improves the inter-rater reliability and SNR of median SSEPs for prognostication among comatose cardiac arrest survivors. To ensure the most reliable prognostic information in comatose post-cardiac arrest survivors, pharmacologic paralysis should be consistently used before recording SSEPs.


  • Cryolipolysis‐associated radial mononeuropathy

    by Nimalan Harinesan, Rajiv Wijesinghe, Michael Hayes, James D. Triplett


  • Open Access

    Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults

    by Divyanshu Dubey, Grayson Beecher, M. Bakri Hammami, Andrew M. Knight, Teerin Liewluck, James Triplett, Abhigyan Datta, Surendra Dasari, Youwen Zhang, Matthew M. Roforth, et al.

    Immune-mediated rippling muscle disease (iRMD) is a rare myopathy characterized by abnormal muscle excitability. It is usually electrically silent, exhibiting wavelike muscle contractions (rippling) and percussion- or stretch-induced muscle mounding.1 In contrast to hereditary rippling muscle disease (hRMD), associated to date with pathogenic variants in caveolin-3 (CAV3) or, less frequently, cavin-1 (CAVIN1) genes, patients with iRMD lack a defined genetic defect.2,3 Responsiveness to immunotherapy supports an autoimmune pathogenesis. Muscle acetylcholine receptor antibody positivity with or without clinical myasthenia gravis (MG) has been reported in association with iRMD, further favoring its potential immune-mediated etiology.4-6


  • Open Access

    Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome

    by James D. Triplett, Jessica Qiu, Billy O'BRien, Sumana Gopinath, Benjamin Trewin, Penelope J. Spring, Mohamed Shaffi, Jerome Ip, Fiona Chan, Luke Chen, et al.

    Background and purpose: Susac syndrome (SuS) is an inflammatory condition of the brain, eye and ear. Diagnosis can be challenging, and misdiagnosis is common.Methods: This is a retrospective review of the medical records of 32 adult patients from an Australasian cohort of SuS patients.Results: An alternative diagnosis prior to SuS was made in 30 patients (94%) with seven patients receiving two or more diagnoses. The median time to diagnosis of SuS was 3 months (range 0.5–100 months). The commonest misdiagnoses were migraine in 10 patients (31%), cerebral vasculitis in six (19%), multiple sclerosis in five (16%) and stroke in five (16%). Twenty‐two patients were treated for alternative diagnoses, 10 of whom had further clinical manifestations prior to SuS diagnosis. At presentation seven patients (22%) met criteria for definite SuS, 19 (59%) for probable SuS and six (19%) for possible SuS. Six patients (19%) presented with brain–eye–ear involvement, 14 with brain–ear (44%), six with brain–eye (19%) and six (19%) with only brain involvement. In patients with the complete triad of symptoms the median delay to diagnosis was 3 months (range 1–9 months) compared to 5.25 months (range 0.5–100 months) for patients with encephalopathy and ocular symptoms at presentation.Conclusions: Susac syndrome patients are frequently misdiagnosed at initial presentation, despite many having symptoms or radiological features that are red flags for the diagnosis. Delayed diagnosis can lead to patient morbidity. The varied ways in which SuS can present, and clinician failure to consider or recognize SuS, appear to be the main factors leading to misdiagnosis.


  • Cardiac and Respiratory Complications of Necrotizing Autoimmune Myopathy

    by James Triplett, Charles D. Kassardjian, Teerin Liewluck, Absar Tahir, Vanda Lennon, Stephen Kopecky, Margherita Milone


  • IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS

    by Shahar Shelly, John R Mills, Jennifer M Martinez-Thompson, Matt M Rofforth, Sean J Pittock, Jay Mandrekar, James Douglas Triplett, Michelle Mauermann, Divyanshu Dubey, C J Klein

    Herein, we address: (1) the occurrence of an IgM-gammopathy in MMN and MADSAM compared with ALS and (2) evaluate the immune treatment response of MMN and MADSAM IgM-monoclonal-gammopathy.


  • P.16Cardiac and respiratory complications in necrotizing autoimmune myopathy

    by J. Triplett, C. Kassardjian, T. Liewluck, A. Tahir, S. Kopecky, M. Milone